{"entity":{"id":"caris-mi-cancer-seek","kind":"drug","name":"MI Cancer Seek","aka":[],"tldr":"The first FDA-approved test that sequences all of a tumour's genes and gene activity at once, used to match patients to several targeted drugs.","summary":"Caris Life Sciences' MI Cancer Seek was approved by the FDA in November 2024 as the first companion diagnostic combining whole-exome and whole-transcriptome sequencing, with claims covering several targeted and immune therapies across breast, colorectal, melanoma and lung cancers alongside tumour-profiling claims. The broad readout underpins Caris's real-world database, and the company's argument is that exome-plus-transcriptome captures fusions, expression and signatures that panels miss. Turnaround and tissue requirements are larger than for targeted panels.","status":"approved","asOf":"2026-09-10","links":[{"label":"Caris: MI Cancer Seek (page moved; nearest live section)","url":"https://www.carislifesciences.com/products-and-services/molecular-profiling/"}],"tags":["test"],"related":[],"cancers":["colorectal","nsclc","melanoma","breast-hr-positive","pancreatic"],"sections":[],"technologies":["cgp","wes-wgs","rna-seq","companion-diagnostic"],"targets":[],"drugs":[],"companies":["caris"],"institutions":[],"pathways":[],"terms":["ngs"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-philip-kras-wild-type-pancreatic-ccr-2022","paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017"],"journals":[],"dependsOn":[],"notes":["What a result means: one sample yields the full genomic picture; the companion claims matter for approved drugs, and the rest supports trial matching.","Pancreatic ductal adenocarcinoma: the DNA and RNA profiling of 2,483 tumours that produced the KRAS wild-type fusion and immune-marker table was run on this laboratory's platform (Philip 2022)."],"brand":"MI Cancer Seek","modality":"Whole-exome and whole-transcriptome companion diagnostic test","mechanism":"Simultaneous whole-exome DNA and whole-transcriptome RNA sequencing from a single tumour sample, with companion diagnostic claims layered on top of the broad profile.","approvals":[{"region":"US","year":2024,"indication":"Companion diagnostic claims across several solid tumours, with tumour-profiling claims"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/caris-mi-cancer-seek/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"company":[{"id":"caris","kind":"company","name":"Caris Life Sciences","route":"/companies/caris/"}],"term":[{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"}],"paper":[{"id":"paper-cohen-cancerseek-multi-analyte-blood-test-science-2018","kind":"paper","name":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","route":"/key-papers/paper-cohen-cancerseek-multi-analyte-blood-test-science-2018/"},{"id":"paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017","kind":"paper","name":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from ASCP, CAP, AMP and ASCO","route":"/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/"},{"id":"paper-philip-kras-wild-type-pancreatic-ccr-2022","kind":"paper","name":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","route":"/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/"}],"biomarker":[{"id":"msi-high","kind":"biomarker","name":"MSI-high (microsatellite instability by PCR or sequencing)","route":"/biomarkers/msi-high/"},{"id":"ras-wild-type","kind":"biomarker","name":"RAS wild-type (extended KRAS and NRAS testing)","route":"/biomarkers/ras-wild-type/"}]}}